Evogene Ltd.

Welcome to EpoGen's first quarter 2026 results conference call. All participants are at present in listen-only mode. Following management's formal presentation, we will open the question and answer session. You may send questions via chat. Please type your name and company before your question. As a reminder, this conference is being recorded May 20, 2026. Before we begin, I would like to caution that certain statements made during this earning conference call by Avergent's management will constitute forward-looking statements that relate to future events. This presentation contains forward-looking statements relating to future events, and Avergent LTD, the company, may from time to time make other statements regarding our outlook or expectations for future financial or operating results and or other matters regarding or affecting us that are considered forward-looking statements, as defined in the U.S. Private Securities Litigation Reform Act of 1995, the PSLRA, and other security laws as amended. Statements that are not statements of historical fact may be deemed to be forward-looking statements. Such forward-looking statements may be identified by the use of such words as believe, expect, anticipate, should, planned, estimated, intent, and potential, or was of similar meaning. We are using forward-looking statements in this presentation when we discussed our value drivers, commercialization effort and timing, product development and launches, estimated market size and milestones, pipeline, as well as our capabilities and technology. Such statements are based on current expectation, estimates, projections, and assumptions. Described opinions about future events involve certain risks and uncertainties, which are difficult to predict and are not guarantees of future performance. We do so caution that certain important factors may affect the company's actual results and could cause such results to differ materially from any forward-looking statement that may be made in this presentation. Therefore, actual future events, performance or achievements and trends in the future may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which are beyond our control, including, without limitation, the aftermath of the recent war between Israel and each of the terrorist groups, Hamas and Hezbollah, Iran and other regional terrorist groups supported by Iran, and any destabilizations in Israel, neighboring territories, or the Middle East region, and those described in greater detail in Evergen's annual report on Form 20F, and in other information Evergen files and furnished with the Israel Security Authorities and the U.S. Securities and Exchange Commission, including those factors under the heading Risk Factors. Acceptance required by applicable security laws. We disclaim any obligation or commitment to update any information contained in this presentation or to publicly release the results of any revision to any statement that may be made to reflect future events or developments or changes in expectations, estimates, projections, and assumptions. The information contained herein does not constitute a prospectus or other offering document, nor does it constitute or form part of any invitation or offer to sell or any solicitation of any invitation or offer to purchase or subscribe for any securities of Evergen or the company, nor shall the information or any part of it or the fact of its distribution from the basis of or be relied on in connection with any action, contract, commitment or relating thereto or the securities of Evergen or the company. The trademarks include herein are the property of the owners thereof and are used for reference purposes only. Such use should not be construed as an endorsement of our product or services. With us on the line will be Ofer Habib, President and CEO of Evergen, and Polina Rabzin, VP Finance of Evergen. Now I would like to turn the call over to Ofer Habib. Mr. Habib, please go ahead.

Thank you for joining Evogen's first quarter 2026 analyst call. In today's call, I will focus on the significant progress Evogen has made over the past quarter and outline the company's key objectives for this year. Joining me for this part of the presentation are Dr. Gaby Tarsik, the company's chief development officer, and Dr. Dan Gelban, CEO of our subsidiary AgPlanus, which focuses on ag-chemical development. Following our remarks, our VP of Finance, Polina Ravzin, will present the financial results. Then, we will open the call for questions. As stated in our previous call, Apogee's mission is clear and focused. to design novel, highly potent small molecules optimized across multiple parameters for drug development and chemicals by leveraging campus AI, our computational generative AI engine. This mission is guided by a strong objective to direct Evogen's resources toward areas where we believe we can create the greatest substantial value. To execute this mission, we made two key strategic decisions. The first one was to focus all of our technology efforts on our proprietary computational engine, Campus AI. In this context, I would like to emphasize that we strongly believe that technological collaborations are essential for advancing our core platform. This belief was clearly demonstrated in the partnership we announced with Google in 2025. In this collaboration, we successfully developed a breakthrough generative engine capable of designing entirely new molecules structure Molecules that are not only highly novel, but also easier to synthesize and better align with multiple product development requirements. The second strategic decision was to streamline our business activity to concentrate on two highly impact markets where campus AI provides a strong competitive advantage, pharma focused on small molecule drug discovery, and agriculture focused on next-generation agrochemicals. To maximize the value of our technology, we adopt a clear and consistent business model across both domains, which is built on two complementary channels. The first channel is establishing strategic collaboration with industry partners For early stage product development, those collaborations help reduce both our scientific and financial risk while accelerating innovation. The second channel is the advancement of our own internally funded products pipeline. In this channel, our goal is to mature those programs further before entering partnerships. allowing us to secure stronger commercial terms with leading industry players. These slides highlight the collaboration and internal programs Evogen was advancing at the end of 2025. In agriculture, we established two strategic collaborations for herbicide development. One with Bayer and another with Corteva. At the same time, we continue advancing our internal funded program focused on novel septoria fungicide. It is important to note that Evogen Act chemical activities began in 2018 and are carried out through our subsidiary, Act Planus. In parallel, our pharmaceutical activity focused on small molecules drug discovery were launched only at the beginning of 2025 as a division of Avogen. At the end of 2025, our first and only announced collaboration in this field was with Tel Aviv University targeting therapies for metabolic diseases linked to a protein aggregation in blood vessels. Now, I would like to present the company's achievements over the last quarter and to date across those three areas, our core technology platform, our pharma activities, and our artchemical activities. We will begin by reviewing the achievements in the area of our core technology platform, Campus AI. In February this year, we announced our second collaboration with Google aimed at integrating agents into Campus. The collaboration is expected to enable capabilities that currently do not exist in the global small molecule discovery process. Our second collaboration with Google focused on developing advanced AI agents to solve complex scientific challenges. Success in this project will enable Evogen to automatically extract valuable insights from scientific publications and create proprietary datasets. These datasets will help us build highly-accurated computational models for characterizing specific scientific parameters. We will then use those models to support the development of new molecules designed in accordance with the requirements of our target product profiles. Overall, these new capabilities are expected to significantly strengthen Evogen's technological leadership and competitive advantage. We will now proceed to reviewing the achievements and activities in the company's pharma division where the most significant growth occurred this year. In the first quarter of the year, the company announced three new collaborations agreements, two with biotech companies and one with an academic institution. In the following slides, Dr. Gaby Kacik, Evogen's CTO, will elaborate on each collaboration. Gaby?

Thank you, Alfred. I am excited to share with you the progress in the pharma division that has taken place since the beginning of the year. In February, we announced a new collaboration with Systasy Bioscience and Ludwig Maximilian University Hospital in Germany. This collaboration focuses on a novel biological target involved in neutrophil-driven hyperinflammatory diseases, such as inflammatory bowel disease, IBD, an area of significant unmet medical need. The collaboration, supported by the prestigious Eureka grant brings together three complementary capabilities. Evogen's KEMPAS AI engine, Cystasis proprietary pathway profiler technology for high content functional validation in patient-specific models, and the clinical expertise of Ludwig Maximilian University Hospital. By integrating AI-driven molecular design, advanced functional biology, and clinical insights from the earliest stages, we aim to accelerate the identification of high-quality drug candidates while building strong long-term therapeutic and commercial value. In January this year, we announced a collaboration with Unravel Biosciences that focuses on a newly discovered target for demyelinating disorders, such as multiple sclerosis. to develop brain-penetrant therapies capable of restoring myelin and improving neurological function. Here, by combining Evogen's Campus AI drug design engine with Unravel's patient-derived molecular profiling capabilities, we are accelerating the identification of drug candidates and addressing a major unmet medical need in a neurodegenerative market exceeding $26 billion, thereby creating significant long-term partnering and commercial opportunities. This collaboration exemplifies the strategic partnerships we are pursuing by bringing together deep biological insight and evidence as that computational chemistry platform to create differentiated first-in-class therapeutic opportunities with strong pharmaceutical licensing potential. In mid-February, we announced an additional collaboration that focuses on addressing chemotherapy resistance, one of the major challenges that limits the effectiveness of current cancer treatments, in collaboration with Dr. Mark Adams and the Queensland University of Technology in Australia. Together, we are targeting a newly identified cellular detoxification pathway that enables tumors to resist cancer therapy. The collaboration integrates Evogen's campus AI generative molecular design engine with advanced cancer genomic expertise to develop novel small molecule inhibitors designed to restore treatment sensitivity. By addressing a key resistance mechanism across multiple cancer types, including non-small cell lung cancer, this program has the potential to generate differentiated oncology candidates with strong clinical and commercial value. I am very proud to present for the first time the Small Molecules Part-Times of Evergen's Pharma Division, a growing and highly promising portfolio that reflects the strengths of our technology, innovation, and strategic collaborations. We are encouraged by the advancement of the molecules generated in collaboration with our partners, and we look forward to seeing these programs progress rapidly into more advanced preclinical and clinical stages. At the same time, we expect additional high-potential projects to join this exciting pipeline, further expanding the opportunities ahead of us. Looking ahead, I am excited to continue sharing updates on meaningful progress we are making across these programs. With that, I would like to conclude my remarks and hand over the call back to Ofer.